Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03970096 | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | recruiting | Phase 2 | 120 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | recruiting | Phase 2 | 216 | City of Hope Medical CenterOTHER | 1 | Mar 10, 2026 |
| clinicaltrials |
| NCT06316856 | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | recruiting | Phase 1 / Phase 2 | 54 | Beijing GoBroad HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05306301 | Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | active not recruiting | Phase 2 | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06253637 | Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program(DARATALL-VHR) | active not recruiting | Phase 2 | 31 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05479994 | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 100 | BeiGeneINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05873712 | Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | recruiting | Phase 2 | 24 | Aseel AlsouqiOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04624633 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | active not recruiting | Phase 2 | 29 | Jennifer R. Brown, MD, PhDOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05336812 | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 52 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06466122 | Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | recruiting | Phase 2 | 30 | Kerry RogersOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT02158091 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | active not recruiting | Phase 1 / Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03580928 | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL(AVO) | active not recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05677919 | Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 72 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06644183 | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) | recruiting | Phase 1 / Phase 2 | 64 | Jennifer R. Brown, MD, PhDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05592015 | Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | recruiting | Phase 2 | 30 | Jonathan BrammerOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06860269 | A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia(GRAALL-2024) | recruiting | Phase 2 / Phase 3 | 1,200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03938987 | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)(ACIT001/EXC002) | recruiting | Phase 1 / Phase 2 | 63 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04895436 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)(ReVenG) | recruiting | Phase 2 | 75 | AbbVieINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT03513562 | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | active not recruiting | Phase 2 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06580301 | Study of YK012 in B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 46 | Excyte Biopharma LtdINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05366218 | Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia(Anti-CD19-ALL) | recruiting | Phase 1 / Phase 2 | 20 | University Hospital TuebingenOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05460533 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07366801 | Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies | recruiting | Phase 2 / Phase 3 | 64 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | active not recruiting | Phase 2 | 150 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06333262 | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 60 | Inhye AhnOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05417165 | Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 80 | Seema BhatOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | recruiting | Phase 2 | 70 | Christine RyanOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | active not recruiting | Phase 2 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07014917 | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL(ESR-23-22182) | recruiting | Phase 2 | 62 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | recruiting | Phase 2 | 22 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03961672 | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 15 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07301138 | BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients | not yet recruiting | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07297914 | Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL(FORUM2) | not yet recruiting | Phase 2 / Phase 3 | 1,000 | Bambino Gesù Hospital and Research InstituteOTHER | 9 | Dec 22, 2025 | clinicaltrials |
| NCT06387121 | Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | recruiting | Phase 2 | 53 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07052695 | Mosunetuzumab for CLL MRD Clearance | recruiting | Phase 1 / Phase 2 | 40 | Inhye AhnOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05168930 | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05194397 | Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors(IAMFIT) | recruiting | Phase 2 | 80 | Children's Hospital of PhiladelphiaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07252336 | A Multicenter Study of CAR-T Cells in Primary Ph+All | recruiting | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04844528 | Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers | recruiting | Phase 2 | 86 | University of UtahOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04963946 | STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia(STAIR) | active not recruiting | Phase 2 | 160 | French Innovative Leukemia OrganisationOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06316427 | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies | recruiting | Phase 1 / Phase 2 | 80 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07070323 | A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies(nanobody CD5) | recruiting | Phase 1 / Phase 2 | 54 | Beijing GoBroad HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07244406 | Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL | recruiting | Phase 2 | 59 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05940961 | Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL | recruiting | Phase 2 | 42 | Sheng-Li Xue, MDOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06530576 | Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia | recruiting | Phase 2 | 48 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06716658 | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 48 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04060277 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 12, 2026source: clinicaltrials